A medic opens the resuscitation kit after a blast. The casualty is pale, the pulse is fast, and the evacuation clock is already running. A vial of tranexamic acid (TXA) is easy to reach. The hard part is deciding whether this casualty is the right patient, whether the dose matches current guidance, and whether giving it now will displace a more urgent action.
TXA is not a substitute for hemorrhage control, blood, evacuation, or reassessment. It is a time-sensitive adjunct. The useful question for a line medic is not “Do we carry TXA?” It is “Which casualty should receive it, by when, and what must happen first?”
For this post, the doctrinal anchor is the Joint Trauma System Damage Control Resuscitation Clinical Practice Guideline, whose page carries an August 29, 2023 update and favors a 2-g TXA bolus for eligible casualties rather than the older 1-g bolus plus 1-g infusion pattern (JTS Damage Control Resuscitation CPG). Check the current CoTCCC guidance in Deployed Medicine before teaching or treating, because the current operational document governs your unit.
The biological reason for speed is fibrinolysis: the injured body can break down forming clots while bleeding continues. The JTS guideline identifies TXA as an option for casualties with significant hemorrhage or risk of hemorrhage, and it places administration inside the first three hours after injury (JTS Damage Control Resuscitation CPG). That window is not a permission to delay care while someone searches for a vial. It is a reason to build TXA into the first hemorrhage-control and resuscitation sweep.
A 2026 exploratory analysis of the PATCH-Trauma randomized trial adds a sharper training point. In adults with major trauma and suspected trauma-induced coagulopathy, the mortality benefit was most apparent when the first dose was given within 90 minutes; the analysis did not show a mortality reduction when treatment began beyond 90 minutes (Ali et al., “Tranexamic Acid Timing and Mortality Impact After Trauma,” PubMed). The study used a 1-g intravenous bolus before hospital arrival followed by a 1-g infusion after arrival, so its timing result should not be confused with the JTS 2-g bolus update.
The evidence is not a single clean answer for every injured patient. The 2023 PATCH-Trauma trial enrolled 1,310 adults with major trauma at risk for trauma-induced coagulopathy. Its primary outcome was six-month survival with a favorable functional outcome, and TXA did not improve that outcome compared with placebo. The trial did find lower 28-day mortality in the TXA group, with no meaningful difference in serious adverse events (Gruen et al., “Prehospital Tranexamic Acid for Severe Trauma,” PubMed). For a medic, that means TXA should not be sold as a promise of neurologic recovery. It is a mortality-focused intervention within a larger treatment sequence.
A 2024 systematic review and meta-analysis found lower 24-hour mortality across 11 studies and 11,259 trauma patients, but its randomized-trial subgroup also signaled higher thromboembolism and infection events (Chen et al., “Effectiveness and safety of prehospital tranexamic acid in patients with trauma,” PubMed). Pooled estimates combine different settings, routes, doses, and patient-selection rules. They cannot replace the indication in current JTS or CoTCCC guidance.
TBI deserves separate attention. In a 2024 subgroup analysis of 541 patients with intracranial hemorrhage from a prehospital TBI trial, a 2-g out-of-hospital bolus was associated with lower 28-day mortality and a lower six-month Disability Rating Scale score than placebo or the 1-g bolus plus 1-g infusion approach; six-month Glasgow Outcome Scale-Extended scores did not differ among groups (Rowell et al., “The effects of prehospital TXA on mortality and neurologic outcomes,” PubMed). The result supports the JTS move toward a 2-g bolus in eligible patients, but it does not mean every altered casualty should receive TXA automatically. The clinical picture, mechanism, bleeding risk, time from injury, and local guidance still matter.
First, treat the casualty in the order that prevents immediate death. Stop compressible hemorrhage with a recommended tourniquet or wound packing, address airway and breathing threats, and begin the movement and resuscitation plan. Those priorities come from the TCCC framework; the current guideline should be checked on Deployed Medicine and in the materials issued by the unit.
Second, make the TXA decision visible. Say the time of injury or last-known-well estimate. Say whether the casualty has significant hemorrhage or a strong risk of hemorrhagic shock. Say whether TXA has been given, the dose, the route, and the time. The receiving team needs a clean handoff, not a loose vial in a pocket. The JTS DCR guideline also emphasizes early blood-product resuscitation, limited crystalloid use, calcium, temperature control, and rapid evacuation as parts of damage-control resuscitation rather than isolated tricks (JTS Damage Control Resuscitation CPG).
Third, train the exception. A casualty can have a dramatic wound and still need an airway maneuver, a tension-pneumothorax intervention, or immediate tourniquet correction before anyone draws up TXA. Another casualty can look better while carrying a mechanism and physiology that make hemorrhage likely. The training problem is not memorizing a drug fact. It is recognizing the indication while protecting the sequence of care.
That is where Global MedOps Command and scenario-based rehearsal fit. Use a MilMedSim training scenario to force the learner to state the injury time, choose the dose from the current unit protocol, document the intervention, and hand it off under evacuation pressure. A good scenario makes the learner earn the medication decision instead of rewarding a reflexive “give TXA” answer.
I have watched good medics turn a medication into a ritual. They see blood, reach for the familiar adjunct, and feel the case moving in the right direction. TXA deserves a place in the kit, but it does not deserve to outrank a tourniquet that is still loose or a casualty who cannot ventilate. The useful habit is simple: control the kill first, identify the time from injury, then give the current dose when the indication is present.
That being said, the evidence is not as clean as a briefing slide. The large PATCH-Trauma trial did not improve six-month functional outcome, while later analyses point toward earlier treatment and possible benefit from a 2-g bolus in selected patients. I am comfortable with the JTS direction because it matches the operational problem: the drug has to reach the right casualty early. I am not comfortable turning that direction into automatic treatment for every trauma patient.
If you are the medic on the ground, put one question into every hemorrhage drill: “What is the injury time, and what will I do next if TXA is not the priority?” If you are a medical officer, audit whether the handoff records dose and time, not just the word “TXA.” Readiness is the ability to make the right small decision while the large problem is still moving.
Follow the current unit protocol and JTS or CoTCCC guidance. The JTS Damage Control Resuscitation CPG places TXA for eligible casualties within three hours, while a 2026 analysis found the clearest signal when the first dose was given within 90 minutes (JTS Damage Control Resuscitation CPG; Ali et al., 2026).
The JTS Damage Control Resuscitation CPG page shows a June 2023 update favoring a 2-g TXA bolus over the older 1-g prehospital bolus followed by a 1-g infusion. Confirm the current CoTCCC and unit protocol before administering it (JTS Damage Control Resuscitation CPG).
No. TXA is an adjunct. The JTS guideline places it alongside direct hemorrhage control, early blood-product resuscitation, calcium, temperature control, and rapid evacuation (JTS Damage Control Resuscitation CPG).
No automatic rule should replace patient assessment and current guidance. A 2024 TBI subgroup analysis found a mortality signal with a 2-g out-of-hospital bolus in patients with intracranial hemorrhage, but six-month functional outcomes were not different across groups (Rowell et al., 2024).
If you're a combat medic, corpsman, flight medic, or any provider treating casualties in the field trying to understand how AI will actually impact your clinical practice — not just the hype — I put together a free practical guide. You can download it here: AI in EM Survival Guide.